Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Pain Therapeutics (PTIE) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 26,760
  • Shares Outstanding, K 46,140
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,150 K
  • 36-Month Beta 2.21
  • Price/Sales N/A
  • Price/Book 1.32
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.38
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.75 on 12/13/12
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.52 +20.19%
on 11/09/16
0.84 -25.60%
on 11/22/16
+0.11 (+20.19%)
since 11/04/16
3-Month
0.51 +22.55%
on 11/04/16
3.00 -79.17%
on 09/20/16
-1.71 (-73.29%)
since 09/06/16
52-Week
0.51 +22.55%
on 11/04/16
3.00 -79.17%
on 09/20/16
-1.27 (-67.11%)
since 12/04/15

Most Recent Stories

More News
Research Reports Initiation on Biotech Stocks -- Spectrum Pharma, Pain Therapeutics, CoLucid Pharma, and CEL-SCI

Stock-Callers.com has initiated coverage on the following Biotechnology companies: Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Pain Therapeutics Inc. (NASDAQ: PTIE), CoLucid Pharmaceuticals Inc. (NASDAQ:...

Pain Therapeutics Reports Q3 2016 Financial Results

Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the third quarter of 2016. Net loss in Q3 2016 was $3.5 million, or $0.08 per share, compared to a net loss in Q3 2015 of $3.7...

Glboal Visceral Pain Therapeutics Pipeline Report 2016 - Research and Markets

Research and Markets has announced the addition of the "Visceral Pain - Pipeline Review, H2 2016" report to their offering.

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Pain Therapeutics, Inc. Class Action and Settlement Hearing - PTIE

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

The Life Sciences Report Examines How Analysts Keep Focus on DURECT's DUR-928

SAN FRANCISCO, CA--(Marketwired - October 07, 2016) - The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT Corp. (NASDAQ: DRRX) to Pain Therapeutics, has not changed the view...

The Life Sciences Report Examines How Analysts Keep Focus on DURECT's DUR-928

SAN FRANCISCO, CA--(Marketwired - October 07, 2016) - The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT Corp. (NASDAQ: DRRX) to Pain Therapeutics, has not changed the view...

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Pain Therapeutics, Inc. Class Action and Settlement Hearing - PTIE

IN THE UNITED STATES DISTRICT COURT

Pain Therapeutics (PTIE) Enters Oversold Territory

Pain Therapeutics Inc. (PTIE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug

Pain Therapeutics Inc.'s (PTIE) shares plunged 51.3% after the company announced that the FDA has issued a complete response letter (CRL) for the new drug application (NDA) for its lead candidate Remoxy....

Is Pain Therapeutics an Incredible Momentum Stock? 3 Reasons Why PTIE Will Be Tough to Beat

Pain Therapeutics (PTIE) is looking especially impressive right now and might be a great candidate for momentum-oriented investors in the near term

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Pain Therapeutics is developing a new generation of opioid painkillers.Opioids are drugs derived from the poppy plant. The company uses technology to reformulate opioid drugs, such as morphine, into new painkillers with improved clinical benefits. The company has four opioid painkillers in Phase II clinical...

See More

Support & Resistance

2nd Resistance Point 0.64
1st Resistance Point 0.62
Last Price 0.63
1st Support Level 0.57
2nd Support Level 0.54

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.